• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Synlogic Inc.

    8/15/25 4:19:22 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYBX alert in real time by email
    S-3/A 1 d89246ds3a.htm S-3/A S-3/A

    As filed with the Securities and Exchange Commission on August 15, 2025

    Registration No. 333-289415

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    AMENDMENT NO. 1

    TO

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SYNLOGIC, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   26-1824804

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    PO Box 30

    Winchester, MA 01890

    (617) 659-2802

    (Address, including zip code and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Mary Beth Dooley

    Principal Executive Officer and Principal Financial Officer

    Synlogic, Inc.

    PO Box 30

    Winchester, MA 01890

    (617) 659-2802

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Daniel Bagliebter, Esq.

    Nishant Dharia, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    919 Third Avenue

    New York, NY 10022

    212-935-3000

     

     


    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement as determined by the registrant.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

      

    Smaller reporting company

     

    ☒

        

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

    THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.

     

     
     


    EXPLANATORY NOTE

    This Amendment No. 1 to the Registration Statement on Form S-3 is being filed solely for the purpose of filing exhibit 4.9 and exhibit 4.10. Accordingly, this Amendment No. 1 consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature pages to the Registration Statement and the filed exhibits. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has been omitted.


    INFORMATION NOT REQUIRED IN PROSPECTUS

    Item 14. Other Expenses of Issuance and Distribution

    The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered. All of the amounts shown are estimated except the SEC Registration Fee and the FINRA Filing Fee.

     

     

     

    SEC registration fee

       $ 22,965  

    Printing and engraving expenses

         *  

    Legal fees and expenses

         *  

    Accountants’ fees and expenses

         *  

    Transfer agent and registrar fees and expenses

         *  

    Miscellaneous expenses

         *  
      

     

     

     

    Total

         *  

     

     
      *

    Fees depend on number of issuances and amount of securities sold and accordingly cannot be estimated at this time.

    Item 15. Indemnification of Directors and Officers

    Section 102 of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

    Section 145 of the Delaware General Corporation Law authorizes a court to award or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act.

    Section 145 of the Delaware General Corporation Law states:

    (a) A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.

    (b) A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to

     

    II-1


    procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    (c) To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsections (a) and (b) of this section or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

    (d) Any indemnification under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and (b) of this section. Such determination shall be made, with respect to a person who is a director or officer of the corporation at the time of such determination:

    (1) By a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum; or

    (2) By a committee of such directors designated by majority vote of such directors, even though less than a quorum; or

    (3) If there are no such directors or if such directors so direct, by independent legal counsel in a written opinion; or

    (4) By the stockholders.

    (e) Expenses (including attorneys’ fees) incurred by an officer or director of the corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys’ fees) incurred by former directors and officers or other employees and agents of the corporation or by persons serving at the request of the corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the corporation deems appropriate.

    (f) The indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to the certificate of incorporation or the bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit or proceeding for

     

    II-2


    which indemnification or advancement of expenses is sought, unless the provision in effect at the time of such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.

    (g) A corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under this section.

    (h) For purposes of this section, references to “the corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

    (i) For purposes of this section, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at the request of the corporation” shall include any service as a director, officer, employee or agent of the corporation which imposes duties on or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation” as referred to in this section.

    (j) The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

    (k) The Court of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. The Court of Chancery may summarily determine a corporation’s obligation to advance expenses (including attorneys’ fees).

    As permitted by Delaware law, our amended and restated certificate of incorporation limits or eliminates the personal liability of our directors and officers to the maximum extent permitted by Delaware law.

    Our amended and restated bylaws provide for indemnification of our directors and executive officers to the maximum extent permitted by the Delaware General Corporation Law.

    In addition, we have entered into indemnification agreements with each of our current directors and executive officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. We also intend to enter into indemnification agreements with our future directors and executive officers.

    We also maintain standard policies of insurance under which coverage is provided to our directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act and to us

     

    II-3


    with respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law.

    The above discussion of our amended and restated certificate of incorporation, our amended and restated bylaws, our indemnification agreements with our current directors and executive officers and Sections 102 and 145 of the Delaware General Corporation Law is not intended to be exhaustive and is respectively qualified in its entirety by such amended and restated certificate of incorporation, such amended and restated bylaws, such indemnification agreements and such statutes.

    To the extent that our directors, officers and controlling persons are indemnified under the provisions contained in our amended and restated certificate of incorporation, Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

    Item 16. Exhibits

    (a) The following exhibits are filed herewith or incorporated herein by reference:

    EXHIBIT INDEX

     

     

     

    EXHIBIT
    NUMBER
       EXHIBIT DESCRIPTION   FILED
    HEREWITH
        INCORPORATED
    BY REFERENCE
    HEREIN FROM
    FORM OR
    SCHEDULE
        FILING
    DATE
        SEC FILE/
    REG.
    NUMBER
     
    1.1**    Form of Underwriting Agreement        
    4.1    Amended and Restated Certificate of Incorporation of the Registrant      

    Form 8-K

    (Exhibit 3.1)

     

     

        10/6/2015       001-37566  
    4.2    Certificate of Amendment to Amended and Restated Certificate of Incorporation      

    Form 8-K

    (Exhibit 3.1)

     

     

        8/28/2017       001-37566  
    4.3    Certificate of Amendment to Amended and Restated Certificate of Incorporation      

    Form 8-K

    (Exhibit 3.2)

     

     

        8/28/2017       001-37566  
    4.4    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Synlogic, Inc., dated June 15, 2023      

    Form 8-K

    (Exhibit 3.1)

     

     

        6/15/2023       001-37566  
    4.5    Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation of Synlogic, Inc., dated September 27, 2023      

    Form 8-K

    (Exhibit 3.1)

     

     

        9/28/2023       001-37566  
    4.6    Amended and Restated Bylaws of the Registrant      

    Form 8-K

    (Exhibit 3.2)

     

     

        10/6/2015       001-37566  
    4.7    Form of Common Stock Certificate      

    Form S-1/A

    (Exhibit 4.2)

     

     

        9/18/2015       333-206544  
    4.8**    Form of Certificate of Amendment or Designation with respect to Preferred Stock        

     

    II-4


    4.9    Form of Senior Indenture     X        
    4.10    Form of Subordinated Indenture     X        
    4.11**    Form of Senior Debt Security        
    4.12**    Form of Subordinated Debt Security        
    4.13**    Form of Warrant Agreement and Warrant        
    4.14**    Form of Rights Agreement and Right Certificate        
    4.15**    Form of Unit Agreement and Unit        
    5.1*    Opinion of Mintz, Levin, Cohn, Ferris, Glovksy and Popeo, P.C.        
    23.1*    Consent of KPMG LLP, independent registered public accounting firm        
    23.2*    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)        
    24.1*    Power of attorney        
    25.1**    Statement of Trustee Eligibility        
    107*    Filing Fee Table        

     

     
      *

    Previously filed

      **

    To be filed by amendment

    Item 17. Undertakings

    (a) The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    II-5


    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

    (i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

    (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

    (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

    (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

    (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

    (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

    (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

    (b) That, for purposes of determining any liability under the Securities Act:

    (i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared effective; and

     

    II-6


    (ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (d) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

    (e) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act (“Act”) in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Act.

     

    II-7


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Winchester, Commonwealth of Massachusetts, on August 15, 2025.

     

    Synlogic, Inc.
    By:  

    /s/ Mary Beth Dooley

      Mary Beth Dooley
      Principal Executive Officer and Principal Financial Officer

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-3 has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE

      

    TITLE

     

    DATE

    /s/ Mary Beth Dooley

    Mary Beth Dooley

      

    Principal Executive Officer and Principal Financial Officer

    (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

      August 15, 2025

    *

    Peter Barrett

       Chairman of the Board of Directors   August 15, 2025

    *

    James Flynn

       Director   August 15, 2025

    *

    Edward Mathers

       Director   August 15, 2025

    *

    Richard P. Shea

       Director   August 15, 2025

     

    *By:  

    /s/ Mary Beth Dooley

      Mary Beth Dooley
      Attorney-in-fact

     

    II-8

    Get the next $SYBX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYBX

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SYBX
    SEC Filings

    View All

    SEC Form EFFECT filed by Synlogic Inc.

    EFFECT - SYNLOGIC, INC. (0001527599) (Filer)

    8/21/25 12:16:04 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Synlogic Inc.

    S-3/A - SYNLOGIC, INC. (0001527599) (Filer)

    8/15/25 4:19:22 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Synlogic Inc.

    S-3 - SYNLOGIC, INC. (0001527599) (Filer)

    8/8/25 4:01:04 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synlogic Reports Third Quarter 2024 Financial Results

    WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

    11/12/24 4:35:09 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic Reports Second Quarter 2024 Financial Results

    WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

    8/8/24 7:00:52 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic Reports First Quarter 2024 Financial Results

    CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

    5/14/24 7:00:28 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Financials

    Live finance-specific insights

    View All

    Synlogic Adopts Limited Duration Stockholders Rights Plan

    CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

    2/20/24 12:15:26 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

    Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

    12/15/22 6:59:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

    Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

    10/18/22 6:59:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

    SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

    11/14/24 4:40:57 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

    SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

    5/16/24 7:44:32 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Synlogic Inc.

    SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

    4/18/24 11:18:42 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

    4 - SYNLOGIC, INC. (0001527599) (Issuer)

    4/29/25 4:46:11 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P was granted 15,000 shares (SEC Form 4)

    4 - SYNLOGIC, INC. (0001527599) (Issuer)

    4/29/25 4:43:44 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

    4 - SYNLOGIC, INC. (0001527599) (Issuer)

    4/3/25 4:30:42 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Synlogic upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

    11/24/21 7:28:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic upgraded by Oppenheimer

    Oppenheimer upgraded Synlogic from Perform to Outperform

    11/24/21 4:55:59 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on Synlogic with a new price target

    SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

    11/11/21 5:14:48 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYBX
    Leadership Updates

    Live Leadership Updates

    View All

    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

    4/1/24 8:00:00 AM ET
    $LCTX
    $SYBX
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

    – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

    3/29/23 6:40:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

    CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

    1/3/23 6:58:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care